Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $0.49, $0.01 worse than the analyst estimate of $0.50. Revenue for the quarter came in at $306.1 million versus the consensus estimate of $306.47 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.